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The muscarinic receptor mediating vasodilation of resistance vesse]s in the rat iso]ated, constant-pressure perfused kidney 
(preconstriction by w- 7 M cirazoline) was characterized by subtype-preferring agonists and se]ective antagonists. The agonists 
produced vasodi1ation with the fol1owing rank order of potency: arecaidine propargy] ester (APE) > 5-methylfurtrethonium = 
methacholine = oxotremorine > (S)-aceclidine > arecaidine 2-butyne-1,4-diyl bisester > 4-Cl-McN-A-343 = (R)-nipecotic acid 
ethyl ester = N-ethyl-guvacine propargyl ester- (R)-aceclidine = (S)-nipecotic acid ethyl ester > McN-A-343. Agonist-induced 
vasodilation disappeared after destruction of the endothelium with detergent. Highly significant correlations of agonist potencies 
for vasodilation were found between rat kidney and guinea-pig ileum submucosal arterioles as weH as agonist potencies at 
smooth muscle muscarinic M3 receptors of the guinea-pig ileum. The rank order of antagonist potencies (4-diphenylacetoxy-N-
methylpiperidine methiodide (4-DAMP) > (R)-hexahydro-difenidol - hexahydro-sila-difenidol > pirenzepine - p-fluoro-
hexahydro-sila-difenidol- himbacine- AF-DX 384- AQ-RA 741 > (S)-hexahydro-difenidol) to attenuate vasodilation to APE 
in rat kidney, correlated significantly with affinities at M3 receptors in submucosal arterioles and in smooth muscle of the 
guinea-pig ileum, but differed from those at M1 and M2 receptors in rabbit vas deferens. The agonist and antagonist potencies 
suggest that vasodilation elicited by muscarinic stimuli in endothelium-intact rat renal vasculature is mediated by functional 
muscarinic M 3 rcceptors. 
Kidney (perfused, rat); Muscarinic receptor agonists; Muscarinic receptor antagonists; Arterioles (submucosal); Ileum; Atrium; 
Vas deferens; Videomicroscopy (guinea pig) 
1. lntroduction 
Muscarinic receptors have been classified on the 
basis of pharmacological evidence into at least three 
subtypes termed M 1, M 2 and M 3 (Hulme et al., 1990). 
Molecular biological evidence indicates that at least 
five genes exist that encode m 1-m 5 receptors (Hulme 
et al., 1990). The m 1-m 3 gene products correspond to 
the M 1-M3 receptors (Hulme et al., 1990; Waelbroeck 
et al., 1990; Dörje et al., 1991b), whilst pharmacological 
candidates for the M 4 receptor have also been tenta-
tively identified in rat striatum, rabbit Jung and some 
cell lines (Hulme et al., 1990; Lazareno et al., 1990; 
Waelbroeck et al., 1990; Dörje et al., 1991a). A func-
tional equivalent of the m 5 gene product has yet to be 
identified. 
Correspondence to: M. Eltze, Department of Pharmacology, 
Byk Gulden Pharmaceuticals, 78467 Konstanz, Germany. Tel. 
49.7531.842617, fax 49.7531.842413. 
Each of the three subtypes, M 1, M 2 and M 3, has 
been demonstrated to exist in vascular preparations 
from different species depending on the tissue and 
function examined (for a recent review, see Eglen and 
Whiting, 1990). In general, M3 receptors mediate en-
dothelium-dependent relaxation, whereas M 1 receptor 
stimulation causes contraction of e.g. canine saphenous 
and femoral veins. Stimulation of prejunctional M 2 
receptors appears to inhibit sympathetic outflow in 
vascular preparations from a number of anatomical 
locations from different species. Contraction may also 
occur due to Stimulation of M 2 (e.g. in rabbit aorta; 
Jaiswal et al., 1991) and M 3 receptors (e.g. bovine and 
porcine coronary artery; Eglen and Whiting, 1990). 
Studies on vascular resistance in the rat isolated 
perfused kidney have provided evidence that nitric 
oxide (NO) mediates the vasodilator response to 
acetylcholine (Bhardwaj and Moore, 1988; Burton et 
al., 1990). Muscarinic receptor sites in rat kidney la-
belled with [3H]quinuclidinyl benzilate ([ 3H]QNB) were 
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located primarily within the smooth muscle of the 
vascular tree and to a lesser extent within the cortical 
and medullary tubules (De Micheie et al., 1989). Auto-
radiographie analysis has located M 3 receptors in 
glomeruli but not in tubules of rat kidney (Rodrigues 
de Miranda et al., 1989) Recently, muscarinic receptors 
in rat kidney cortex have been characterized to be of 
the M3 subtype (Blankesteijn et al., 1993). However, no 
detailed functional characterization of the muscarinic 
receptor subtype(s) involved in the various renal effects 
evoked by muscarinic stimuli in this speci"es has been 
performed so far. 
The aim of the present study was to characterize the 
muscarinic receptor responsible for the endothelium-
dependent vasodilation in rat kidney. Forthis purpose, 
the ability of a series of subtype-preferring agonists to 
elicit relaxation as weil as the potency of selective 
antagonists to inhibit this muscarinic effect were deter-
mined in the isolated, perfused rat kidney. Agonist and 
antagonist patendes were compared with those ob-
tained at M3 receptors in guinea-pig ileum submucosal 
arterioles (Bungardt et al., 1992), at M1 and M2 recep-
tors in rabbit vas deferens (Eltze, 1988), as well as at 
atrial M2 and ileal M3 receptors of the guinea-pig. 
2. Materials and methods 
2.1. Rat isolated perfused kidney 
The experiments were performed on kidneys taken 
frorn normotensive rats (Sprague-Dawley, male, 400-
450 g, Wiga, Sulzfeld, Germany ), similarly to the 
method described previously (Eltze et al., 1991). Briefly, 
after the aorta adjacent to the left renal artery bad 
been cannulated and the abdominal vena cava cut, the 
kidney was removed and perfused at a constant pres-
sure. of 100 cm H 20 with prewarrned (37°C) Tyrode 
solution of the following composition (mM): NaCI 
137.0, KCI 2.7, CaC1 2 1.25, MgC1 2 1.1, NaHC03 12.0, 
NaH 2P04 0.42, Ca-EDTA 0.026, glucose 5.6, addition-
ally containing L-arginine hydrochloride 0.03 and indo-
methacin 0.01, gassed with a mixture of 95% 0 2-5% 
C02• The prerenal perfusate flow was measured con-
tinuously using an electromagnetic flowmeter. 
2.1.1. Agonist potency 
Each experiment consisted of a 40-min equilibration 
period during which renal perfusate flow stabilized at 
17.4 ± 3.6 mljmin (mean ± S.D., n = 51). Following 
this period, a second reservoir containing the vasocon-
strictor agent, cirazoline (lo- 7 M), which was an ap-
propriate concentration to reduce renal perfusate flow 
between 62-83% (resulting flow == 4.8 ± 1.9 mljmin; 
mean ± S.D., n ==51), was connected via a three-way 
stopcock to continuously perfuse the kidney. Once the 
resulting constriction had stabilized, increasing doses 
of the muscarinic agonists (100 ~A-l aqueous bolus) were 
injected within 2 s into the renal inflow tract and the 
resulting vasodilation was recorded. The -log ED50 
values (mol) were determined graphically from semi-
logarithmic plots. At the end of drug administration 
the maximal effect was determined by bolus injection 
of 3 x 10- 7 mol arecaidine propargyl ester (APE). The 
perfusion was then changed to Tyrode solution without 
vasoconstrictor. The kidneys were repeatedly con-
stricted in cycles of 45 min. Each preparation was used 
to evaluate the responses of the renal vasculature to 
maximally six different agonists in random order, pro-
vided that (a) the vasoconstriction in response to 10-7 
M cirazoline could be exactly reproduced and (b) the 
vasodilator response to bolus injections of 3 x 10-7 
mol APE remained stable. No significant time-rlepen-
dent changes in the vascular responscs to the agonists 
could be detected. 
2.1.2. Removal of endothelium 
Vascular endothelium was removed by perfusion of 
the kidney for 5 min with Tyrode solution containing 
3-[(3-cholamidopropyl)-dimethylammonio]-1-propane-
sulfonate (CHAPS, 0.2 mgjml) similar to the metbad 
described by Bhardwaj and Moore (1988). The degree 
of endothelial darnage was verified functionally by the 
inability of bolus injections of muscarinic agonists to 
elicit a vasodilation of more than 7% in cirazoline-pre-
constricted (10- 7 M) organs. Functional integrity of 
the vascular smooth muscle after CHAPS treatment 
was investigated with the endothelium-independent va-
sodilator, nitroprusside oo-7 mol). 
2.1.3. Antagonist potency 
The increase in renal flow due to bolus injections of 
5 X 10-9 mol APE ( = ED70 of its own maximal effect) 
during perfusion of the kidneys with cirazoline oo- 7 
M) in the absence of the muscarinic antagonists was 
taken to be 100%. The percentage inhibition of this 
effect in the presence of increasing concentrations of 
the antagonists perfused tagether with cirazoline for 20 
min was calculated. Thus, complete individual concen-
tration-response curves for an antagonist were gener-
ated in five or six kidneys, enabling calculation of an 
EC50 value, i.e., the molar concentration for half-maxi-
mal antivasodilator effect. 
2.2. Guinea-pig isolated ileum submucosal arterioles 
Submucosal plexus preparations were obtained from 
the small intestine of guinea-pigs as described previ-
ously (Bungardt et al., 1992). Briefly, the preparations 
were perfused continuously at 8-10 mljmin with Ty-
rode solution gassed with 95% 02-5% co2 at 32-36°C 
(composition, see under 2.3). The outside diameter of 
submucosal arterioles was monitored by using a com-
puter-assisted videomicroscopic system (Diamtrak). 
Muscarinic agonists were applied cumulatively by su-
perfusion to vessels previously constricted by 10-5 M 
(- )-noradrenaline. The apparent agonist potency was 
expressed as its EC50 value, i.e. the molar concentra-
tion inducing 50% of the individual maximal vasodila-
tion. 
2.3. Guinea-pig isolated left atrium and ileum 
Guinea-pigs (300-400 g) of either sex were killed by 
cervical dislocation. The removed Jeft atrium was set 
up in a 6-ml organ bath under 0.5 g tension in oxy-
genated (95% 0 2-5% C02 ) Tyrode solution at 32°C 
composed of (mM): NaCJ 137.0, KCJ 2.7, CaCJ 2 1.8, 
MgC1 2 1.05, NaHC03 11.9, NaH 2P04 0.42 and glucose 
5.6, and was paced electrically (2 Hz, 3 ms, 5 V) by 
means of platinum electrodes. The negative inotropic 
effect of the muscarinic agonists was measured 
as change in isometric tension and pD2 values 
(-log EC50s) were calculated. In antagonist studies, 
APE was used as agonist, the antagonists being equili-
brated with the atria for at least 30 min (Feifel et al., 
1990). 
Strips of ileallongitudinal smooth muscle suspended 
in Tyrode solution (composition as used for the atrium) 
were maintained at 32°C and gassed with 95% 0 2-5% 
C02 under a resting Ioad of 0.5 g (Feifel et al., 1990). 
Isotonic contractions were elicited by cumulative addi-
tion of muscarinic agonists at 30-min intervals and pD2 
values (-log EC50s) were determined graphically from 
semi-logarithmic plots. For assessment of antagonist 
affinity, concentration-response curves to acetylcholine 
or.APE were obtained in the absence and presence of 
the antagonists equilibrated with the tissue for at least 
20 min. 
Both in guinea-pig atrium and ileum, apparent effi-
cacies (intrinsic activity, i.a. values) were determined by 
comparing the maximum response to the agonists with 
that to APE (i.a. = 1.00). 
2. 4. Rahbit vas deferens 
Male New Zealand white rabbits were killed by i.v. 
injection of pentobarbital sodium (60 mgjkg) and 
exsanguination. Vasa deferentia were removed and 
divided into four segments, two prostatic portions of 1 
cm and two epididymal portions each approximately 
1.5 cm in Iength. Each tissue was folded in two over a 
platinum electrode in a 10-ml organ bath and con-
nected via a thread to a force-displacement transducer. 
A second platinum ring electrode was placed at the top 
of the bathing fluid for continuous field stimulation 
(0.05 Hz, 0.5 ms, 30 V). The bathing fluid (composition 
in mM: NaCI 118.0, KCI 4.7, CaCJ 2 2.5, MgS04 0.6, 
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KH 2 P04 1.2, NaHC03 25.0, glucose 11.1, yohimbine 
0.001) was maintained at 31°C and gassed with 95% 
0 2-5% C02• A resting tension of 0.75 g was applied 
and neuragenie twitch contractions were measured iso-
metrically and recorded on a multi-channel recorder 
(Eltze, 1988). 
Agonist potencies (pD2 values) and apparent effica-
cies (i.a. values) at muscarinic M 1 receptors in rabbit 
vas deferens were determined on close prostatic seg-
ments suspended in the nutrient solution mentioned 
above, with the exception that the CaC1 2 concentration 
was reduced to 1.8 mM. 4-Cl-McN-A-343 was used as 
refcrence agonist. 
Antagonists affinities for M 1 and M 2 receptors were 
obtained from concentration-response curves either to 
McN-A-343 for inhibition (M 1 receptors) or to carba-
chol for potentiation (M 2 receptors) of neurogenic 
twitch contractions in the absence and presence of 
antagonists (45-min exposure time) (Eitze, 1988). 
2.5. Data analysis 
For the assessment of antagonist affinity in rabbit 
vas deferens and guinea-pig atrium and ileum, EC 50 
values of agonists were determined for the control and 
the antagonist-shifted concentration-response curves 
using at least four different antagonist concentrations 
{log interval = 0.48). Each concentration of an anlago-
nist was tested 3-4 times and the ratios of agonist 
molar EC50 values obtained in the absence and pres-
ence of antagonists were calculated. Schild plots were 
made, using linear regression by the method of least 
squares, to estimate the slope of the regression lines 
(Arunlakshana and Schild, 1959). pA 2 values were 
obtained from Schild plots in which the slopes of the 
regression lines were constrained to 1.00 (Tallarida et 
al., 1979). In those few cases (table 2) where the slopes 
differ significantly from unity (P < 0.05), the pA 2 val-
ues should be regarded as a purely experimental quan-
tity. 
2.6. Linearregressions 
Linear regressions were calculated by the method of 
least squares in order to determine the correlation 
coefficient r and the slope of regression ß. Significance 
of differences of the slope from unity was assessed with 
t-tests. 
2.7. Drugs 
Arecaidine propargyl ester hydrobromide (APE), 
guvacine propargyl ester hydrobromide (GPE), guvaco-
line hydrobromide, N-ethyl-guvacine propargyl ester 
hydrobromide (NEN-APE), arecaidine 2-butyne-:-1,4-
diyl bisester p-toluene sulfonate (bis-ABE), (R)-
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Fig. 1. Dose-response curves of muscarinic agonists to evoke renal vasodilation in constant-pressure perfused rat kidney during continuous 
perfusion of 10- 7 M cirazoline. Given are means of n =5-7 experiments (S.D. < 9%, not shown). Ordinate: percent vasodilation related to the 
maximum effect to APE (3 X 10-7 mol) in the same preparation. Abscissa: -log mol of the agonists administered by bolus injection. For the sake 
of clarity, not all agonists investigated (with numbering in table 1) are depicted. 
aceclidine perchlorate and (S)-aceclidine hydrobro-
mide, 4-[[N -( 4-chlorophenyl)-carbamoyl]oxy ]-2-butynyl-
trimethylammonium iodide (4-Cl-McN-A-343), hexahy-
dro-sila-difenidol hydrochloride (HHSiD) and its p-flu-
oro analogue (p-F-HHSiD), (R)- and (S)-enantiomers 
of hexahydro-difenidol hydrochloride [ (R)-HHD and 
(S)-HHD] were synthesized in our laboratories. Oxo-
tremorine sesquifumarate (Merck, Darmstadt, Ger-
many). (R)- and (S)-nipecotic acid ethyl ester tartrate 
((R)- and (S)-NAEE) were kindly donated by Prof. 
Krogsgaard-Larsen (Copenhagen, Denmark). Nuven-
zepine hydrochloride (Dompe Pharmaceuticals, Milan, 
ltaly). Mequitamium iodide (Laboratori Guidotti, Pisa, 
I taly ). 4-[[N-(3-Chlorophenyl)carbamoyl]oxy ]-2-butynyl-
trimethylammonium chloride (McN-A-343) was pur-
chased from RBI (Cologne, Germany). ( ± )-Methacho-
line chloride (EGA Chemie, Steinheim, Germany). 
Pirenzepine dihydrochloride, ( ± )-6-chloro-5, 10-dihy-
dro-5-[( 1-methyl-4-piperidinyl)acetyl]-llH-dibenzo-
[b,e]diazepin-11-one hydrochloride (UH-AH 37), ( ±)-
5, 11-dihydro-11-[[[2-[2-( (dipropylamino )methyl )-1-pi-
peridinyl]ethyl]aminocarbonyl]-6H -pyrido(2,3-b X 1,4 )-
benzodiazepin-6-one (AF-DX 384), 11-[[4-[4-(diethyl-
amino)buty0-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyr-
ido(2,3-bX1,4)-benzodiazepin-6-one (AQ-RA 7.41) 
(Prof. B. Wetzel, Thomae, Biberach, Germany}. Hirn-
RAT~DNEY--------------------------------------------------, 
100 
ANT AGONlSTS 
9 8 7 6 s 
-log (Antagonist) M 
Fig. 2. Concentration-response curves for inhibition by musearlnie antagonists of renal vasodilation induced by bolus injection of 5 x 10- 9 mol 
APE during continuous cirazoline perfusion oo-7 M) in rat kidney. Given are means of n =5-6 experiments (S.O.< 10%, not shown). Ordinate: 
% inhibition of APE-induced vasodilation. Abscissa: -log M of the antagonists equilibrated with the kidney for 20 min. Numbering of the 
antagonists refers to table 2. 
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3. Results 
3.1. Rat perfused kidney 
3.1.1. Effect of drugs on non-preconstricted kidneys 
bacine hydrochloridewas kindly donated by Prof. W.C. 
Taylor (University of Sydney, Australia). ldaverine 
(Duphar BV, Weesp, The Netherlands). (±)-Telen-
zepine dihydrochloride, 4-diphenylacetoxy-N-methyl-
piperidine methiodide (4-DAMP), 5-methylfurtreth-
onium iodide (MeFur) (Byk Gulden, Konstanz, Ger-
many). Cirazoline hydrochloride (Synthelabo, Paris, 
France). Disodium nitroprusside (Schwarz, Monheim, 
Germany). rac-Cromakalim (Smith Kline Beecham, 
U .K.). All other drugs (arecoline hydrobromide, ( ± )-
muscarine chloride, carbamoylcholine chloride (car-
bachol), hexamethonium bromide, tetrodotoxin, at-
ropine sulfate, papaverine hydrochloride and 3-[(3-
cholamidopropyl)-dimethylammonio ]-1-propanesulfo-
nate (CHAPS)) were purchased from Sigma (Munich, 
Germany). 
Without vasoconstrictor stimuli, bolus injection of 
papaverine (up to 10-6 mol) proved to be ineffective. 
lnjection of other smooth muscle relaxants, e.g. nitro-
prusside (up to 10-6 mol) and cromakalim (up to 10-7 
mol) into the renal inflow tract did not increase perfu• 
sion flow of the kidneys by more than 5%, indicating 
an essential absence of intrinsic vascular tone. None of 
the muscarinic agonists and antagonists listed in tables 
1 and 2, respectively, when injected into the renal 
inflow tract up to 10-7 mol, enhanced or diminished 
basal flow by more than 7%. 
TABLE 1 
Potency of muscarinic agonists to elicit vasodilation in perfused rat kidney preconstricted with cirazoline oo- 7 M) and their potency (pD2 
values) at muscarinic M3 receptors in guinea-pig ileum (GPI), M1 receptors in rabbit vas deferens (RVD) and M2 receptors in guinea-pig atrium 
(GPA). 
Given are means with 95% confidence Iimits or S.D. of n = 6-7 kidneys and n = 6-12 experiments for those in the other preparations. Maximal 
effects in rat kidney and apparent efficacies (i.a. values) in guinea-pig ileum and atrium are related to APE. Apparent efficacies (i.a. values) in 
rabbit vas deferens are related to the total inhibition of twitch amplitude. 
Drug Rad kidney pD2 (i.a.) 
-log ED50 (mol) M3 (GPI) M 1 (RVD) M2 (GPA) (% max. effect) 
(l)APE 9.44 (8.8-9.9) 7.58 (7.5-7.6) 7.74 (7.5-7.9) 8.19 (8.1-8.3) 
(100) (1.00) (1.00) (1.00) 
(2) MeFur 8.65 (7.7-9.6) 7.62 (7.5-7.7) 6.89 (6. 7-7.1) 6.46 (6.4-6.5) 
(80± 12) (1.00) (1.00) (1.00) 
(3) Methacholine 8.60 (7.1-9.9) 7.51 (7.2-7.8) 6.51 (6.2-6.8) 7.08 (7.0-7.2) 
(64± 6) (1.00) (1.00) (1.00) 
(4) Oxotremorine 8.56 (7.7-9.4) 7.39 (7. J -7.7) 7.77 (7.7-7.9) 7.65 (7.6-7.8) 
(95±5) (1.00) (1.00) (1.00) 
(.5) Carbacbol 8..5.5 (7..5-9.6) 6.67 (6.6-6. 7) 6.77 (6.7-6.9) 6.90 (6.8-7.0) 
(80± 14) (1.00) (1.00) (1.00) 
(6) GPE 8.25 (7.2-9.3) 7.13 (6.9-7.3) 7.28 (7.1-7.4) 6.97 (6.8-7. J) 
(M3± 15) (1.00) (1.00) (1.00) 
(7) (S)-Aceclidine 8.15 (7.3-9.0) 6.52 (6.4-6.6) 6.60 (6.5-6.7) 6.48 (6.4-6.6) 
(96± R) (1.00) (1.00) (1.00) 
(8) Arecoline 7.77 (6.9-8.7) 6.46 (6.3-6.6) 6.69 (6.6-6.8) 6.84 (6.8-6.9) 
(77 ± 7) (1.00) (1.00) (1.00) 
(9) bis-ABE 7.70 (7.0-8.4) 6.27 (6.1-6.4) 6.94 (6.8-7.1) 7.10 (7.0-7.2) 
(79±6) (0.89 ± 0.09) (1.00) (1.00) 
(1 0) Guvacoline 7.58 (6.4-8.7) 6.43 (6.1-6. 7) 5.95 (5.9-6.0) 6.61 (6.5-6.7) 
(69± 6) (1.00) (1.00) (1.00) 
(11) 4-CI-McN-A-343 6.82 (6.2-7.4) 5.35 (5.2-5.5) 7.06 (7.0-7.1) 5.26 (5.1-5.4) 
(63± 10) (1.00) (1.00) (0.77±0.12) 
(12) (R)-NAEE 6.70 (6.5-6.9) 5.78 (5. 7-5.9) inactive 5.82 (5.7-5.9) 
(92± 2) (1.00) (pA 2 = 5.34) (0.87 ± 0.13) 
(13) NEN-APE 6.60 (6.2-7.0) 4.65 (4.4-4.9) inactive 6.48 (6.4-6.6) 
(71 ± 12) (0.46 ± 0.08) (pA 2 = 5.81) (0. 76 ± 0.05) 
(14) (R)-Aceclidine 6.47 (6.2-6. 7) 5.29 (5.2-5.4) 5.07 (5.0-5.2) 5.50 (5.4-5.6) 
(65±2) (0.84±0.17) (0.86 ± 0.17) (1.00) 
(15) (S)-NAEE 6.46 (6.1-6.9) 5.19 (5.1-5.3) inactive 4.77 (4.7-4.8) 
(73±8) (0.93±0.04) (pA 2 = 4.75) (0.58 ± 0.13) 
(16) McN-A-343 6.19 (5.6-6.7) 4.96 (4.8-5.1) 6.57 (6.5-6.7) 4.87 (4.5-5.3) 
(51± 12) (0.51 ± 0.07) (1.00) (0.49 ± 0.1 0) 
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3.1.2. Effeet of musearinie agonists on kidneys preeon-
strieted by cirazoline 
During vasoconstriction induced by cirazoline (10- 7 
M), which evoked a stable and reproducible decrease 
in renal flow of 72 ± 11% (mean ± S.D., n =51; result-
ing perfusion flow between 2.9 and 6.7 mljmin), injec-
tions of increasing doses of e.g. APE (10- 12-3 X 10-7 
mol), MeFur (lo- 11-2 X 10-7 mol), bis-ABE (10- 10-
3 X 10-7 mol) and 4-Cl-McN-A-343 (10- 9-3 X 10- 7 
mol) caused a dose-dependent and reversible dilation 
in the rat kidney (fig. 1). Related to the maximal 
vasodilation by 3 x 10-7 mol APE (defined as 100%), 
which itself reversed the cirazoline-induced flow reduc-
tion by 67 ± 17% (mean ±S.O., n =51), high doses of 
the other · agents only partially reached this value, i.e. 
those producing more than 80% vasodilation were ox-
otremörine, (S)-aceclidine, (R)-NAEE, MeFur, GPE, 
bis-ABE and carbachol, those not reaching 80% were 
(S)-NAEE, . arecoline, guvacoline, methacholine, 4-Cl-
McN-A-343, NEN-APE and McN-A-343. The ED50 
values of the agonists are listed in table 1. 
The dose-response curves of the potent agonists, 
e.g. APE, MeFur and carbachol, to evoke vasodilation 
were more shallow than those obtained for the weaker 
Fig. 3. Diagrammatic comparison of the potency (pD2 values) of 
subtype-preferring musearlnie agonists to inhibit twitch contractions 
in rabbit vas deferens (M 1 receptor), to elicit negative inotropy in 
guinea-pig left atrium (M2 receptor) and to evoke contraction in 
guinea-pig ileum loogitu~inal smooth muscle (M3 receptor). NEN-
APE was inactive as agonist at M1 receptors, but behaved as a 
competitive antagonist (pA 2 = 5.81). 
agonists, e.g. 4-Cl-McN-A-343, (R)-NAEE and NEN-
APE. One possible explanation could be that steady 
state conditions after injection of the lower doses of 
the agonists are less closely attained than at higher 
doses during perfusion flow. Additionally, it must be 
kept in mind that muscarinic agonist-induced vasodila-
tion per se might promote agonist removal from the 
kidney during increased perfusion flow. 
3.1.3. E/feet of CHAPS 
Administration of CHAPS-containing (0.2 mgjml) 
Tyrode solution for 5 min reduced basal perfusion flow 
from 18.6 ± 0.4 mljmin to 15.4 ± 0.7 mljmin (mean ± 
S.D., n = 6). No vasoconstrictor or vasodilator effect of 
bolus injections of APE, MeFur, 4-Cl-McN-A-343 and 
methacholine (up to 3 X 10-7 mol) was observed after 
perfusion of the kidney with CHAPS. The reduction in 
perfusion flow in response to continuous cirazoline 
administration (lo- 7 M) was slightly enhanced from 
5.2 ± 2.2 (control) to 4.4 ± 1.2 mljmin following 
CHAPS administration (means ± S.O., n = 6). In kid-
neys so treated, APE, MeFur, 4-Cl-McN-A-343 and 
metbachoHne (up to 3 X 10-7 mol) did not evoke va-
sodilation by more than 5% of the values observed for 
the agonists in CHAPS-untreated organs and no vaso-
constrictor response to these muscarinic agonists was 
seen. In contrast, the vasodilator response to nitroprus-
side (lo- 7 mol) remained unchanged by CHAPS treat-
ment (increase in perfusion flow by approximately 75% 
prior to and after CHAPS administration). 
3.1.4. Effect of musearlnie antagonists 
The antagonists did not significantly alter the vaso-
constriction due to cirazoline (10- 7 M), but attenuated 
the vasodilation due to APE (5 X 10- 9 mol). Concen-
tration-response curves of the antagonists are shown in 
fig. 2. In most cases, high concentrations of the antago-
nists abolished the effect of APE by more than 80%. 
The -log EC50 (M) values for the antagonists are 
summarized in table 2. 
The concentration-response curves for UH-AH 37, 
telenzepine, p-F-HHSiD and (S)-HHD were steeper 
than those for the other antagonists investigated. As-
suming that a steady equilibrium was reached for all 
antagonists during the 20-min perfusion period, the 
steep concentration-response curves of UH-AH 37, 
telenzepine, p-F-HHSiD and (S)-HHD might be ex-
plained by their weak displacement from muscarinic 
receptors due to bolus injection of the agonist APE 
because of slow off-kinetics. 
3. 2. Guinea-pig ileum submueosal arterioles 
MeFur and bis-ABE, applied in a cumulative fash-
ion to guinea-pig ileum submucosal arteriolar prepara-
tions produced concentration-dependent dilation of the 
(- )-noradrenaline-preconstricted vessel (lo-s M). 
These responses were resistant to blockade by 
tetrodotoxin (10- 6 M) and hexamethonium (10- 4 M), 
thereby confirming the direct activation of muscarinic 
receptors on the submucosal arteriole. Both agonists 
produced a maximal vasodilation of 85 ± 4% (MeFur; 
n = 6; mean ± S.E.M.) and 86 ± 3% (bis-ABE; n = 5; 
mean ± S.E.M.), respectively, with EC 50 values ( ± S.E.M.) of 0.24 ± 0.07 x 10- 6 M (n = 6) and 1.59 ± 
0.29 X 10-6 M (n == 5). 
3.3. Potency of agonists at musearlnie M1, M2 and M3 
receptors 
All agonist responses were characterized as mus-
carinic in nature in that their activities were blocked by 
pirenzepine (10- 7 M) in rabbit vas deferens, AQ-RA 
741 (3 x 10- 7 M) in guinea-pig atrium and p-F-HHSiD 
TABLE 2 
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(5 X 10-7 M) in guinea-pig ileum. Tetrodotoxin (10- 6 
M) and hexamethonium (10-4 M) did not block ago-
nist activities in guinea-pig atrium and ileum. 
When close prostatic segments of the rabbit vas 
deferens were used, electrical field stimulation elicited 
phasic contractions of the 'rapid twitch' type, which 
could be inhibited concentration dependently by mus-
carinic agonists, e.g. APE, MeFur, bis-ABE, McN-A-
343, 4-Cl-McN-A-343, oxotremorine, carbachol, (S)-
and (R)-aceclidine (not shown), acting at inhibitocy 
prejunctional M1 receptors (Eltze, 1988). Except for 
the partial agonist, (R)-aceclidine (i.a. = 0.86), all other 
compounds behaved as full agonists. In contrast, NEN-
APE, (R)- and (S)-NAEE were inactive at M1 recep-
tors in rabbit vas deferens an·d behaved as competitive 
antagonists. The potencies (pD2 values) and apparent 
efficacies (i.a. values) obtained for the agonists at M1 
receptors are listed in table 1. 
Potency of muscarinic antagonists (-log EC50 ) to attenuate vasodilation due to bolus injections of 5 X 10-9 mol APE in rat kidney 
preconstricted by 10~ 7 M cirazoline, as wen as affinity constants (pA2 values) from constrained Schildplots for antagonism at muscarinic M3 
receptors in guinea-pig ileum (GPI) and at MI and M2 receptors in rabbit vas deferens (RVD). 
The results are presented as means± S.E.M. of n =5-6 for rat kidney and n = 12-16 experiments for pA2 determination in guinea-pig ileum and 
rabbit vas deferens. y = slope of Schild plot. 
Drug Rat kidney pA2 
-log EC50 (M) M3 (GPI) MI (RVD) M2(RVD) 
(l) Atropine 8.42±0.08 8.99±0.07 9.53±0.06 9.05±0.11 a 
y = 1.09 ± 0.07 y = 1.13 ±0.11 y = 1.68±0.02 b 
(2)4-DAMP 8.30±0.09 8.83±0.17 c 9.12±0.08 a 8.16±0.10 ~ 
y - 1.01 ± 0.03 y -1.14±0.02 y = 1.08 ± 0.02 
(3)(R)-HHD 7.51 ±0.06 8.35±0.04 d 8.71±0.05 d 6.83±0.07 
y = 0.92±0.07 y = 1.26±0.09 b y = 1.15 ± 0.19 
(4)HHSiD 7.26±0.08 7.76±0.06 7.92±0.07 a 6.54±0.07 a 
y - 1.06 ± 0.07 y = 1.09 ± 0.03 y = 0.86 ± 0.07 
(5) UH-AH 37 6.96±0.05 8.07±0.08 e 8.64±0.08 e 7.15±0.12 e 
y = 1.16 ± 0.13 y = 1.04 ± 0.08 y = 1.22±0.10 b 
(6) Telenzepine 6.90±0.04 7.87±0.08 8.86±0.06 a 7.51±0.09 a 
y = 1.07±0.05 y = 1.49±0.05 b y = 1.19±0.04 b 
(7) Mequitamium 6.72±0.11 8.14±0.04 8.68±0.08 8.36±0.06 
y = 1.01 ± 0.07 y - 1.04 ± 0.24 y = 1.25 ± 0.08 b 
(8) Pirenzepine 6.19±0.09 6.87 ±0.20 c 8.08±0.04 6.23±0.08 a 
y = 0.89 ± 0.11 y = 1.14 ± 0.06 y = 1.07 ± 0.04 
(9) Nuvenzepine 6.12±0.07 7.03 ±0.09 e 7.74±0.08 e 6.63±0.10 e 
y -1.05±0.13 y -1.07 ±0.13 y = 1.02 ± 0.03 
(10) p-F-HHSiD 6.00±0.07 7.49±0.09 c 6.77±0.07 e 6.09±0.11 e 
y = 1.01 ± 0.24 y = 1.11 ±0.12 y = 1.09 ± 0.21 
(11) Himbacine 5.89±0.05 7.10±0.09 8.05±0.10 a 8.06±0.09 a 
y.,., 0.98±0.09 y = 1.16 ± 0.03 y = 1.00 ± 0.08 
(12) Idaverine 5.72±0.11 7.77±0.04 9.02±0.11 8.72±0.05 
y = 1.01 ± 0.08 y = 1.34±0.09 b y = 1.12 ± 0.08 
(13) AF-DX 384 5.72±0.09 7.41 ±0.07 8.61±0.09 8.58±0.10 
y = 0.98±0.04 y = 1.23±0.11 b y = 1.42±0.09 b 
(14) AQ-RA 741 5.40±0.10 6.97±0.07 8.44±0.06 8.62±0.09 
y = 0.87±0.13 y = 1.20±0.16 y = 1.69±0.17 b 
(15) (S)-HHD 4.64±0.11 6.07±0.05 d 5.97±0.04 d 5.25±0.04 
y = 0.87±0.17 y = 0.87 ±0.10 y = 0.96±0.13 
• Data taken from Eltze (1988). b Slope significantly different from unity (P < 0.05). c Data taken from Eltze and Figala (1988). d Data taken 
from Feifel et al. (1990). e Data taken from Eltze et al. (1992). 
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Similarly, the agonists caused negative inotropy due 
to Stimulation of muscarinic M2 receptors in left atrium, 
and smooth muscle contraction due to stimulation of 
M3 receptors in ileum of the guinea-pig. Potencies 
(pD2 values) and apparent efficacies (i.a. values) of the 
agonists at cardiac M 2 and smooth muscle M 3 recep-
tors are also listed in table 1. 
Comparison of data obtained at different muscarinic 
receptor subtypes (table 1) shows that most compounds 
did not discriminate between M 1, M2 and M3 recep-
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Fig. 4. Top: Relationship between the potencies of muscarinic ago-
nists to evoke vasodilation in rat kidney (table 1) and to relax (- )-
noradrenaline-preconstricted guinea-pig submucosal arterioles 
(GPSMA). Bottom: relationship between the potency of muscarinic 
antagonists to attenuate APE-induced vasodilation in rat kidney 
(table 2) and their functional affinities (pA 2 values) for M 3 receptors 
in GPSMA. All antagonist and most of the agonist data (except for 
MeFur and bis-ABE, this study) obtained in GPSMA were taken 
from Bungardt et al. (1992). 
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Numbering of drugs refers to table 1. 
tors. However, APE was the most potent agonist, pos-
sessing a small preference for M2 receptors (Lambrecht 
et al., 1993). The bivalent Iigand, bis-ABE (Moser et 
al., 1990), exhibited high potency at M 1 and M2 and a 
5- and 6-fold lower potency at M3 receptors, respec-
tively (M 2 = M 1 > M 3). A different potency rank order 
was found for MeFur (M 3 > M 1 ~ M 2 ), methacholine 
(M 3 > M2 > M 1) as weil as McN-A-343 and its 4-chloro 
derivative (M 1 > M2 = M 3) (Lambrecht et al., 1993). 
The (R)- and (S)-enantiomers of NAEE (Zorn et al., 
1987) were non-selective agonists at M 2 and M3 recep-
tors (eudismic ratios- 11.2 and 3.9, respectively), but 
competitive antagonists at M 1 receptors (eudismic ratio 
= 3.9). NEN-APE was a potent partial agonist at M2 
receptors (pD2 = 6.48) but about 100-fold less potent 
at ileal M 3 receptors (pD2 = 4.65), and behaved as a 
competitive antagonist at MI receptors (pA 2 = 5.81) 
(Wolf-Pflugmann et al., 1989). Fig. 3 summarizes 
graphically the results obtained with these subtype-pre-
ferring muscarinic agonists. 
3.4. Affinity of antagonists at muscarinic Mb M2 and M 3 
receptors 
Neurogenie contractions of the rabbit isolated vas 
deferens to field stimulation could be inhibited concen-
tration dependently by the M 1-selective agonist, McN-
A-343 (10- 7-2 X 10-6 M) (Lambrecht et al., 1993), or 
potentiated by carbachol (10- 8-2 X 10-7 M) (Eltze, 
1988). Both effects were antagonized in a surmount-
able fashion by the muscarinic antagonists tested in the 
present study, and the pA 2 values of the compounds at 
inhibitory prejunctional M1 and excitatory postjunc-
tional M 2 receptors (Eitze, 1988) are listed in table 2. 
Among the antagonists investigated, 4-DAMP, piren-
zepine, telenzepine, UH-AH 37, HHSiD, (R)-HHD 
and nuvenzepine clearly showed a preference (factor ~ 
10) for MI receptors, whereas atropine, himbacine, 
mequitamium, p-F-HHSiD, AQ-RA 741, AF-DX 384 
and (S)-HHD antagonized M1 and M 2 receptor-media-
ted responses with similar potency (factor < 5; table 2). 
The affinity of idaverine appeared to be equally high 
for M 1 and M 2 receptors in rabbit vas deferens. All 
antagonists inhibited the contractions of the guinea-pig 
ileum evoked by acetylcholine or APE. There was a 
concentration-dependent parallel shift to the right of 
the agonist concentration-response curves without ei-
ther basal tension or maximum responses being af-
fected. The antagonists showed quite wide variations in 
their antimuscarinic potencies at smooth muscle M3 
receptors, their pA 2 values differing by up to three 
orders of magnitude (table 2). 
In all cases, the Schild plots were linear and most 
slopes of the regression lines were not significantly 
different from unity (P > 0.05) (table 2), indicating 
simple competitive antagonism at the three muscarinic 
receptor subtypes. 
3.5. Linearregressions 
In the first instance, we compared the potency of a 
number of agonists and antagonists at muscarinic re-
ceptors in rat kidney with their effects in resistance 
vessels of the submucosal arterioles of the guinea-pig 
small intestine. In the latter preparation, only func-
tional muscarinic M 3 receptors have been demon-
strated, the activation of which causes vasodilation 
(Bungardt et al., 1992). An excellent correlation re-
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sulted (r = 0.988, P < 0.001; ß = 0.98 not significantly 
different from unity, P > 0.05) on comparison of the 
potencies of seven agonists (APE > methacholine = 
oxotremorine = MeFur = carbachol > bis-ABE > 4-CI-
McN-A-343) to evoke vasodilation in both vascular 
preparations (fig. 4, top). There was also a highly 
significant correlation (r = 0.9498, P < 0.001; ß = 1.00 
not significantly different from unity, P > 0.05) when 
the potencies of eight antagonists to inhibit APE-in-
duced vasodilation in rat kidney were compared with 
5 
6 7 8 9 10 
Rahbit vas deferens: pA2 (M1) 
Fig. 6. Relationships between the potencies of musearlnie antago-
nists to attenuate APE-induced vasodilation in rat kidney and (top) 
their affinities for musearlnie M3 receptors in guinea-pig ileum, 
(middle) M 2 receptors in rabbit vas deferens, as weil as (bottom) 
their affinities for muscarinic M 1 receptors in rabbit vas deferens, 
respectively. Numbering of drugs refers to table 2. 
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their pA 2 values for M3 receptor antagonism in 
guinea-pig submucosal arterioles (fig. 4, bottom). 
Comparing the potendes of muscarinic agonists to 
attenuate cirazoline-induced renal vasoconstriction 
with the potencies from contraction sturlies with mus-
carinic M3 receptors in guinea-pig ileum (table 1), a 
highly significant correlation resulted (fig. 5, top; r = 
0.95, P < 0.001; ß = 0.95 not significantly different from 
unity, P > 0.001). Weak correlations were obtained 
when comparing agonist potencies in rat kidney with 
the respective pD2 values from experiments on M2 
receptors in guinea-pig atrium (fig. 5, middle; r = 0.87, 
P < 0.001; ß = 0.90 not significantly different from 
unity, P > 0.05) or on M 1 receptors in rabbit vas defer-
ens (fig. 5, bottom; r = 0.61, P < 0.01; ß = 0.81 signifi-
cantly different from unity, P < 0.01). 
A highly significant correlation also resulted from 
comparison of -log EC50 values of the antagonists 
derived from the rat kidney experiments with their 
respective pA 2 values at muscarinic M 3 receptors in 
guinea-pig ileum (fig. 6, top; r = 0.91, P < 0.001; ß = 
1.24 significantly different from unity, P < 0.05). In 
contrast, no significant correlation was obtained be-
tween the -log EC50 values of the antagonists from 
the rat kidney experiments and pA 2 values of the 
antagonists at M 2 receptors in rabbit vas deferens (fig. 
6, middle; r = 0.29, P > 0.05; ß = 0.27 significantly dif-
ferent from unity, P < 0.001). A weak correlation re-
sulted when the antagonist potencies in rat kidney 
were compared with M 1 receptor affinities in rabbit vas 
deferens (fig. 6, bottom; r = 0.66, P < 0.01; ß = 0.76 
significantly different from unity, P < 0.05). 
4. Discussion 
4.1. General considerations 
In the past, the existence of a cholinergic system 
within the kidney was the object of controversy (Di 
Bona, 1982). While there is now strong evidence for 
muscarinic receptors in the kidney (Garg, 1992), the 
potential source of acetylcholine in this organ is less 
clear. Specific binding of [3 H]QNB has been demon-
strated in rat kidney membranes. The majority of these 
renal muscarinic binding sites were suggested to be 
primarily localized postsynaptically within the smooth 
muscle of the renal vascular tree and to a lesser extent 
within cortical and medullary tubules (Yamada et al., 
1986). In addition, cholinergic markers such as acetyl-
cholinesterase, choline acetyltransferase and a high-af-
finity choline uptake system, have been suggested to be 
present in mammalian kidney (Pirola et al., 1989). 
Recently, muscarinic M3 binding sites in rat kidney 
cortex have been identified, probably located in vascu-
lar tissue (Biankesteijn et aJ., 1993). 
In vitro sturlies on the (- )-noradrenaline-pre-
constricted, constant-flow perfused rat kidney sug-
gested that vasodilator muscarinic receptors mediate 
the endothelium-dependent decrease in perfusion 
pressure (Bhardwaj and Moore, 1988). The present 
study was therefore designed to further characterize 
this muscarinic receptor, using a series of subtype-pre-
ferring agonists and antagonists, including three pairs 
of enantiomers: (R)- and (S)-aceclidine (Lambrecht, 
1976), -NAEE (Zorn et al., 1987) and -HHD (Feifel et 
al., 1990). The results obtained provide convincing evi-
dence that a single functional muscarinic receptor, the 
M3 subtype, mediates muscarinic vasodilation in rat 
renal resistance vessels. 
4.2. Agonist studies 
Arnong the agonists investigated in the three tissues 
containing M 1 (rabbit vas deferens), M 2 (guinea-pig 
Ieft atrium) and M3 receptors (guinea-pig ileum), the 
functional subtype involved can be characterized by 
means of four agonists exhibiting different rank orders 
of potencies (fig. 3). M 1: 4-Cl-McN-A-343 = bis-ABE 
= MeFur ~ NEN-APE; M 2: bis-ABE > NEN~APE = 
MeFur > 4-Cl-McN-A-343; M3: MeFur > bis-ABE > 
4-Cl-McN-A-343 > NEN-APE. 
The agonists tested in the present study, dose de-
pendently increased perfusion flow in rat kidney previ-
ously preconstricted by the continuous presence of 
cirazoline. With the exception of McN-A-343, they 
produced maximal effects between 63 and 96% (re-
lated to the maximal vasodilation elicited by APE; 
fig. 1 ). The rank order of potency was: APE > MeFur 
= methacholine = oxotremorine == carbachol > GPE > 
(S)-aceclidine > arecoline = bis-ABE = guvacoline > 
4-Cl-McN-A-343 = (R)-NAEE = NEN-APE = (R)-ace-
clidine = (S)-NAEE > McN-A-343. This is consistent 
with the potency profile of the agonists (a) in the 
guinea-pig submucosal arteriolar preparation (fig. 4), 
where only M 3 subtype vasodilator muscarinic recep-
tors have been demonstrated (Bungardt et al., 1992), 
and (b) as observed in contraction experiments with 
the longitudinal smooth muscle preparation of the 
guinea-pig ileum (fig. 5), the functional muscarinic 
receptor of which has been characterized as the M 3 
subtype (Eglen et al., 1992). These results suggest that 
muscarinic M 3 receptors mediate the vasodilation in 
rat kidney. 
4.3. Antagonist studies 
Besides some unselective antagonists, i.e. atropine, 
mequitamium (Renzetti et al., 1990; this study) and 
(S)-HHD (Feifel et al., 1990) which did not discrimi-
nate between muscarinic M 1, M 2 and M3 receptor 
subtypes, pirenzepine (Hulme et al., 1990), telenzepine 
(Eltze, 1988), UH-AH 37 (Doods and Mayer, 1989; 
Wess et al., 1991) and nuvenzepine (Eltze et al., 1992) 
clearly distinguished M 1 from M 3 and M 2 receptors (M 1 > M3 ~ M2 ) (table 2). The antagonists, 4-DAMP (Hulme et al., 1990), (R)-HHD (Feifel et al., 1990) and 
HHSiD (Lambrecht et al., 1988), consistently showed 
high er affinity to both M 1 and M 3 receptors than to 
M2 receptors (M 1 = M3 > M 2), whereas p-F-HHSiD 
(Lambrecht et al., 1988) clearly discriminated between 
all muscarinic receptor subtypes investigated (M 3 > M 1 
> M2 ) (table 2). In accordance with affinities deter-
mined for idaverine at different muscarinic receptor 
binding sites (Lucot et al., 1991), antimuscarinic poten-
cies of this antagonist at both M 1 and M 2 receptors in 
rabbit vas deferens were similar and about 10 times 
higher than at ileal M3 receptors (M 1 = M2 > M3). 
The putative cardioselective antagonists, himbacine 
(Gilani and Cobbin, 1986; Eltze, 1988), AF-DX 384 
(Eberlein et al., 1989) and AQ-RA 741 (Doods et al., 
1991), showed higher affinity to both M2 and M1 than 
to M3 receptors (M 2 = M1 > M3) (table 2). The failure 
of himbacine, AF-DX 384 and AQ-RA 741 to discrimi-
nate between functional responses at muscarinic M1 
and M2 receptors in rabbit vas deferens contrasts with 
reports on the ability of the antagonists to distinguish 
between these receptor types in binding sturlies 
(Lazareno and Roberts, 1989; Doods et al., 1991; Dörje 
et al., 1991b). However, although pharmacological 
(Eltze, 1988) and immunological techniques using sub-
type-specific antisera (Dörje et al., 1991a) have shown 
that rabbit vas deferens is endowed only with M 1 and 
M 2 receptors, the inability of these antagonists to 
discriminate M1 from M2 receptor-mediated responses 
in rabbit vas deferens remains unclear and deserves 
further investigation. 
All antagonists concentration dependently and re-
versibly abolished the vasorelaxant response to bolus 
injection of APE in rat kidney. Their -log EC50 values 
for half-maximal inhibition of the vasorelaxant effect of 
APE significantly correlated with their affinities (pA 2 
values) obtained in functional experiments with two 
established muscarinic M3 receptor systems, (a) the 
submucosal arteriolar preparation (fig. 4) (Bungardt et 
al., 1992), and (b) the ileal smooth muscle of the 
guinea-pig (fig. 6) (Eglen et al., 1992). In contrast, the 
profile of antagonist potencies (fig. 6) is not at all 
consistent with the presence of functional M 1 and M 2 
receptors in rat kidney. In addition, calculation of the 
eudismic ratio for the two enantiomers of HHD in rat 
kidney (741) and comparison of this value with data 
obtained at M1 (550), M2 (38) and M3 receptors (240) 
further excludes the M2 subtype for mediating vasodi-
lation in rat kidney. Thus it can be concluded also from 
the antagonist characteristics that the functional mus-
carinic receptor mediating vasodilation in rat perfused 
kidney is of the M3 subtype. 
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4.4. Possible localization and funetion of renovaseular 
musearlnie receptors 
In the rat isolated perfused kidney, (- )-noradrena-
line constricts both preglomerular and postglomerular 
vessels, but only constriction of the former is sensitive 
to the Ca2+ channel antagonist, nisoldipine (Loutzen-
hiser et al., 1984). The a 1-adrenoceptor agonist, cirazo-
Iine, used in the present study has been shown to evoke 
pressor responses in the pithed rat which depend on 
both entry of extracellular Ca2+ and the release of 
Ca2 + from intracellular sources (Nichols and Ruffolo, 
1986). Although it is reasonable to suggest that cirazo-
line may also exert renal microvascular actions at sites 
similar to (- )-noradrenaline, the localization of reno-
vascular dilation produced by Stimulation of M 3 recep-
tors cannot be deduced from our experiments. How-
ever, it has been shown previously by vessel diameter 
observations via television microscopy in the split hy-
dronephrotic rat kidney preparation that acetylcholine 
produced significant dilation of all preglomerular ves-
sels (arcuate and interlobular artefies and afferent 
arterioles) and postglomerular efferent arterioles, its 
effect being greater at afferent than at efferent arteri-
oles near the glomerulus (Fleming et al., 1987). Such a 
dilator pattern in response to acetylcholine is consis-
tent with reports that it substantially increases renal 
blood flow but has little or no effect, on glomerular 
filtration rate (Burton et al., 1990). A surprising obser-
vation was that hemoglobin inhibited the effect of 
acetylcholine only in the efferent, but not in the affer-
ent arteriole. Hence, acetylcholine appears to release 
nitric oxide (NO) only in the efferent arteriole and a 
different relaxing factor in the afferent arteriole 
(Loutzenhiser et al., 1990). 
In anaesthetized rats, endogenous or acetylcholine-
stimulated release of NO may play an important role in 
the local regulation of renal cortical blood flow (Wald er 
et al., 1991). Infusion of acetylcholine into the renal 
artery of anaesthetized rats increased only cortical 
flow, while medullary interstitial infusion increased 
both cortical and papillary blood flow. Only papillary 
blood flow was selectively reduced by inhibition of NO 
synthesis, thus indicating a role in the control of papil-
lary blood flow by local production of NO in the renal 
medulla. A selective reduction in papillary blood flow 
by M 3 receptor Stimulation may therefore be associ-
ated with sodium and water retention (Mattson et al., 
1992). 
4.5. Summary and conc/usion 
In summary, the present study investigated the mus-
carinic receptors in resistance vessels of rat isolated 
perfused kidney. The muscarinic receptor which medi-
ates endothelium-dependent vasodilation of the cirazo-
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line~preconstricted renal vasculature was characterized 
by determining the potencies of a series of subtype-
preferring agonists and the affinities of various selec-
tive antagonists. The results provide convincing evi-
dence that a single muscarinic receptor, the M3 sub-
type, mediates muscarinic vasodilation in rat kidney, 
which disappears after destruction of the endothelium 
by means of detergent. In endothelium-denuded rat 
kidney, muscarinic agonists failed to evoke any vascular 
effect at all. 
Acknowledgements 
The authors gratefully acknowledge the skillful technical assis-
tance of Mrs. H. König, Mrs. C. Bürkle, Mrs. A. Bott and Mrs. S. 
Conzelmann. The work was supported by the Fonds der Chemischen 
Industrie (G.L., E.M., R.T.) and the Deutsche Forschungsgemein-
schaft (G.L., R.T.). 
References 
Arunlakshana, 0. and H.O. Schild, 1959, Some quantitative uses of 
drug antagonists, Br. J. Pharmacol. 14, 48. 
Bhardwaj, R. and P.K. Moore, 1988, Endothelium-derived relaxing 
factor and the effects of acetylcholine and histamine on resis-
tance blood vessels, Br. J. Pharmacol. 95, 835. 
Blankesteijn, W.M., H.L.M. Siero, J.F. Rodrigues de Miranda, Y.J.B. 
Van Megen and F.G.M. Russe!, 1993, Characterization of mus-
carinic receptors in rat kidney, Eur. J. Pharmacol. (Mol. Pharma-
col. Section) 244, 21. 
Bungardt, E., E. Vockert, R. Feifel, U. Moser, R. Tacke, E. 
Mutschler, G. Lambrecht and A. Surprenant, 1992, Characteriza-
tion of muscarinic receptors mediating vasodilation in guinea-pig 
ileum submucosal arterioles by the use of computer-assisted 
videomicroscopy, Eur. J. Pharmacol. 213, 53. 
Burton, G.A., S. MacNeil, A. de Jonge and J. Haylor, 1990, Cyclic 
GMP release and vasodilatation induced by EDRF and atrial 
natriuretic factor in the isolated perfused kidney of the rat, Br. J. 
Pharmacol. 99, 364. 
De Michele, M., F. Amenta and C. Cavallotti, 1989, Autoradio-
graphie localization of muscarinic receptors within the rat kidney, 
Eur. J. Pharmacol. 169, 297. 
Di Bona, G.F., 1982, The functions of renal netves, Rev. Physiol. 
Biochem. Pharmacol. 94, 75. 
Doods, H. and N. Mayer, 1989, UH-AH 37, an ileal-selective mus-
carinic antagonist that does not discriminate between M 2 and M 3 
binding sites, Eur. J. Pharmacol. 161, 215. 
Doods, H., M. Entzeroth and N. Mayer, 1991, Cardioselectivity of 
AQ-RA 741, a novel tricyclic antimuscarinic drug, Eur. J. Phar-
macol. 192, 147. 
Dörje, F., A.l. Levey and M.R. Brann, 199la, Immunological detec-
tion of muscarinic receptor subtype proteins (m1-m5) in rabbit 
peripheral tissues, Mol. Pharmacol. 40, 459. 
Dörje, F., J. Wess, G. Lambrecht, R. Tacke, E. Mutschier and M.R. 
Brann, 1991b, Antagonist binding profiles of five cloned human 
muscarinic receptor subtypes, J. Pharmacol. Exp. Ther. 256, 727. 
Eberlein, W.G., W. Engel, G. Mihm, K Rudolf, B. Wetze!, M. 
Entzeroth, N. Mayer and H.N. Doods, 1989, Structure-activity 
relationships and pharmacological profile of selective tricyclic 
antimuscarioics, Trends Pharmacol. Sei. 10 (Suppl.), 50. 
Eglen, R.M. and R.L. Whiting, 1990, Heterogencity of vascular 
muscarinic receptors, J. Auton. Pharmacol. 10, 233. 
Eglen, R.M., N. Adham and R.L. Whiting, 1992, Acute desensitiza-
tion of muscarinic receptors in the isolated guinea-pig ileal longi-
tudinal muscle, J. Auton. Pharmacol. 12, 137. 
Eltze, M., 1988, Muscarinic M 1- and Mrreceptors mediating oppo-
site effects on neuromuscular transmission in rabbit vas deferens, 
Eur. J. Pharmacol. 151, 205. 
Eltze, M. and V. Figala, 1988, Affinity and selectivity of biperiden 
enantiomers for muscarinic receptor subtypes, Eur. J. Phannacol. 
158, 11. 
Eltze, M., R. Boer, K.H. Sandersand N. Kolassa, 1991, Vasodilata-
tion elicited by 5-HT1A receptor agonists in constant-pressure 
perfused rat kidney is mediated by blockade of a 1A·adrenocep-
tors, Eur. J. Pharmacol. 202, 33. 
Eltze, M., E. Mutschier and G. Lambrecht, 1992, Affinity profiles of 
pizotifen, ketotifen and other tricyclic antimuscarinics at mus-
carinic receptor subtypes M 1, M 2 and M 3, Eur. J. Pharmacol. 
211, 283. 
Feifel, R., M. Wagner-Röder, C. Strohmann, R. Tacke, M. Wael-
broeck, J. Christophe, E. Mutschier and G_ Lambrecht, 1990, 
Stereoselective inhibition of muscarinic receptor subtypes by the 
enantiomers of hexahydro-difenidol and acetylenic analogues, Br. 
J. Pharmacol. 99, 455. 
Fleming, J.T., N. Parekh and M. Steinhausen, 1987, Calcium antago-
nists preferentially dilate preglomerular vessels of hydronephrotic 
kidney, Am. J. Physiol. 22, F1157. 
Garg, L.C., 1992, Actions of adrenergic and cholinergic drugs on 
renal tubular cells, Pharmacol. Rev. 44, 81. 
Gilani, A.S.H. and L. Cobbin, 1986, The cardioselectivity of him-
bacine: a muscarinic receptor antagonist, Naunyn-Schmiedeb. 
Arch. Pharmacol. 332, 16. 
Hulme, E.C., N.J.M. Birdsall and N.J. Buckley, 1990, Muscarinic 
receptor subtypes, Ann. Rev. Pharmacol. Toxicol. 30, 633. 
Jaiswal, N., R.K. Jaiswal and KU. Malik, 1991, Muscarinic 
receptor-mediated prostacyclin and cGMP synthesis in cultured 
vascular cells, Mol. Pharmacol. 40, 101. 
Lambrecht, G., 1976, Struktur- und Konformations-Wirkungs-Be-
ziehungen heterocyclischer Acetylcholinanaloga. I. Muskarin-
wirkung enantiomerer 3-Acetoxychinuclidine und 3-Acetoxypi-
peridine, Eur. J. Med. Chem. 11, 461. 
Lambrecht, G., R. Feifel, B. Forth, C. Strohmann, R. Tacke and E. 
Mutschler, 1988, p-Fluoro-hexahydro-sila-difenidol: the first 
M2ß-selective muscarinic antagonist, Eur. J. Pharmacol. 152, 193. 
Lambrecht, G., U. Moser, U. Grimm, 0. Pfaff, U. Hermanni, C. 
Hildebrandt, M. Waelbroeck, J. Christophe and E. Mutschler, 
1993, New functionally selective muscarinic agonists, Life Sei. 52, 
481. 
Lazareno, S. and F.F. Roberts, 1989, Functional and binding studies 
with muscarinic M 2-subtype selective antagonists, Br. J. Pharma-
col. 98, 309. 
Lazareno, S., N.J. Buckley and F.F. Roberts, 1990, Characterization 
of muscarinic M4 binding sites in rabbit Jung, chicken heart, and 
NG 108-15 cells, Mol. Pharmacol. 38, 805. 
Loutzenhiser, R., M. Epstein, C. Horton and P. Sonke, 1984, Rever-
sal of the calcium antagonists nisoldipine of norepinephrine-
induced reduction in GFR: evidence for preferential antagonism 
of preglomerular vasoconstriction, J. Pharmacol. Exp. Ther. 232, 
382. 
Loutzenhiser, R., K. Hayashi and M. Epstein, 1990, Evidence for 
multiple endothelium-derived relaxing factors (EDRFs) in the 
renal microcirculation: hemoglobin inhibits actylcholine (ACH} 
induced vasodilation of efferent, but not afferent arterioles, Kid· 
ney Int. 37, 373. 
Lucot, J.B., K.J. Van Charldorp and M.T.M. Tulp, 1991, Idaverine, 
an Mr vs. M3-selective muscarinic antagonist, does not prevent 
motion sickness in cats, Pharmacol. Biochem. Behav. 40, 345. 
Mattson, D.L., R.J. Roman and A.W. Cowley, 1992, RoJe of nitric 
oxide in renal papillary blood flow and sodium excretion, Hyper-
tension 19, 766. 
Moser, U., M. Galvan, A. Immei-Sehr, E. Mutschier and G. Lam-
brecht, 1990, Muscarinic activity of arecaidine bivalent ligands 
with conformationally restricted spacers, Eur. J. Pharmacol. 183, 
1991. 
Nichols, A.J. and R.R. Ruffolo, 1986, The relationship between 
alterations in a 1-adrenoceptor reserve by phenoxybenzamine and 
benextramine and the sensitivity of cirazoline-induced pressor 
responses to inhibition by nifedipine, Eur. J. Pharmacol. 126, 297. 
Pirola, C.J., A.L. Alvarez, M.S. Balda, S. Finkielman and V.E. 
Nahmod, 1989, Evidence for cholinergic innervation in dog renal 
tissue, Am. J. Physiol. 257, F746. 
Renzetti, A.R., D. Barone and M. Criscuoli, 1990, High-affinity 
binding of mequitamium iodide (LG 30435) to muscarinic and 
histamine H 1 receptors, Eur. J. Pharmacol. 182, 413. 
Rodrigues de Miranda, J.F., H.L.M. Siero, Y.J.B. Van Megen and 
C.A.M. Van Ginneken, 1989, Characterization of muscarinic re-
ceptors in rat kidney, Trends Pharmacol. Sei. 10 (Suppl.), 109. 
Tallarida, R.J.A., A. Cowan and M.W. Adler, 1979, pA 2 and recep-
tor differentiation: A statistical analysis of competitive antago-
nism, Life Sei. 25, 637. 
355 
Waelbroeck, M., M. Tastenoy, J. Camus and J. Christophe, 1990, 
Binding of selective antagonists to four muscarinic receptors (M 1 
to M4 ) in rat forebrain, Mol. Pharmacol. 38, 267. 
Walder, C.E., C. Thiemerrnann and J.R. Vane, 1991, The involve-
ment of endothelium-derived relaxing factor in the regulation of 
renal cortical blood flow in the rat, Br. J. Pharmacol. 102, 967. 
Wess, J., G. Lambrecht, E. Mutschler, R.M. Brann and F. Dörje, 
1991, Selectivity profile of the novel muscarinic antagonist UH-
AH 37 determined by the use of cloned receptors and isolated 
tissue preparations, Br. J. Pharmacol. 102, 246. 
Wolf-Pflugmann, M., G. Lambrecht, J. Wessand E. Mutschler, 1989, 
Synthesis and muscarinic activity of a series of tertiary and 
quaternary guvacine esters structurally related to arecoline and 
arecaidine propargyl ester, Arzneim. Forsch./Drug Res. 39, 539. 
Yamada, S., H.l. Yamamura and W.R. Roeske, 1986, Effect of 
chemical sympathectomy with 6-hydroxydopamine on a- and ß-
adrenoceptors and musearlnie cholinoceptors in rat kidney, Eur. 
J. Pharmacol. 121, 345. 
Zorn, S.H., R.S. Duman, A. Giachetti, R. Micheletti, E. Giraldo, P. 
Krogsgaard-Larsen and S.J. Enna, 1987, (R)-Nipecotic acid ethyl 
ester: A direct-acting cholinergic agonist that displays greater 
efficacy at M2 than at M1 muscarinic receptors, J. Pharmacol. 
Exp. Ther. 242, 173. 
